/

Società

Me

Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

228 comunicati stampa

Guarda tutti i comunicati

29/07/2026

Titoli e azioni

Biotecnologia

Sanità

Farmaceutica

Salute

Merck Announces Fourth-Quarter 2026 Dividend

Fonte

Merck & Co., Inc.

Emittente

1.00

0

24/07/2026

Industria

Salute

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Fonte

Merck & Co., Inc.

Emittente

1.00

0

16/07/2026

Industria

Scienza

Igiene alimentare

Fitness

Medicina - Varie

Cardiologia

Biotecnologia

Sanità

Farmaceutica

Salute

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Fonte

Merck & Co., Inc.

Emittente

1.00

0

15/07/2026

Web e Social Network

Telefonia e Varie

Eventi

Industria

Scienza

Biotecnologia

Farmaceutica

HIV, AIDS e malattie autoimmuni

Salute

Igiene alimentare

Medicina - Varie

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Fonte

Merck & Co., Inc.

Emittente

1.00

0

15/07/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Industria

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Fonte

Merck & Co., Inc.

Emittente

1.00

0

10/07/2026

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

Industria

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

01/07/2026

Web e Social Network

Telefonia e Varie

Finanza

Mercato azionario

Biotecnologia

Farmaceutica

Salute

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Fonte

Merck & Co., Inc.

Emittente

1.00

0

29/06/2026

Igiene alimentare

Politica Interna

Medicina - Varie

Biotecnologia

HIV, AIDS e malattie autoimmuni

Salute

Politica Locale

Farmaceutica

Sanità

Mercato del lavoro

Industria

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Fonte

Merck & Co., Inc.

Emittente

1.00

0

25/06/2026

Industria

Oncologia

Igiene alimentare

Salute

Medicina - Varie

Farmaceutica

Biotecnologia

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

24/06/2026

Industria

Oncologia

Igiene alimentare

Salute

Medicina - Varie

Farmaceutica

Biotecnologia

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Fonte

Merck & Co., Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0